Literature DB >> 28113004

Development of an opioid-related Overdose Risk Behavior Scale (ORBS).

Enrique R Pouget1, Alex S Bennett1, Luther Elliott1, Brett Wolfson-Stofko1, Ramona Almeñana1, Peter C Britton2,3, Andrew Rosenblum1.   

Abstract

BACKGROUND: Drug overdose has emerged as the leading cause of injury-related death in the United States, driven by prescription opioid (PO) misuse, polysubstance use, and use of heroin. To better understand opioid-related overdose risks that may change over time and across populations, there is a need for a more comprehensive assessment of related risk behaviors. Drawing on existing research, formative interviews, and discussions with community and scientific advisors an opioid-related Overdose Risk Behavior Scale (ORBS) was developed.
METHODS: Military veterans reporting any use of heroin or POs in the past month were enrolled using venue-based and chain referral recruitment. The final scale consisted of 25 items grouped into 5 subscales eliciting the number of days in the past 30 during which the participant engaged in each behavior. Internal reliability, test-retest reliability and criterion validity were assessed using Cronbach's alpha, intraclass correlations (ICC) and Pearson's correlations with indicators of having overdosed during the past 30 days, respectivelyInternal reliability, test-retest reliability and criterion validity were assessed using Cronbach's alpha, intraclass correlations (ICC) and Pearson's correlations with indicators of having overdosed during the past 30 days, respectively.
RESULTS: Data for 220 veterans were analyzed. The 5 subscales-(A) Adherence to Opioid Dosage and Therapeutic Purposes; (B) Alternative Methods of Opioid Administration; (C) Solitary Opioid Use; (D) Use of Nonprescribed Overdose-associated Drugs; and (E) Concurrent Use of POs, Other Psychoactive Drugs and Alcohol-generally showed good internal reliability (alpha range = 0.61 to 0.88), test-retest reliability (ICC range = 0.81 to 0.90), and criterion validity (r range = 0.22 to 0.66). The subscales were internally consistent with each other (alpha = 0.84). The scale mean had an ICC value of 0.99, and correlations with validators ranged from 0.44 to 0.56.
CONCLUSIONS: These results constitute preliminary evidence for the reliability and validity of the new scale. If further validated, it could help improve overdose prevention and response research and could help improve the precision of overdose education and prevention efforts.

Entities:  

Keywords:  Drug use; opioids; overdose; risk behavior

Mesh:

Substances:

Year:  2017        PMID: 28113004      PMCID: PMC5522769          DOI: 10.1080/08897077.2017.1282914

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  31 in total

1.  Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors.

Authors:  C Chabal; M K Erjavec; L Jacobson; A Mariano; E Chaney
Journal:  Clin J Pain       Date:  1997-06       Impact factor: 3.442

2.  Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP).

Authors:  Hammam Akbik; Stephen F Butler; Simon H Budman; Katherine Fernandez; Nathaniel P Katz; Robert N Jamison
Journal:  J Pain Symptom Manage       Date:  2006-09       Impact factor: 3.612

3.  Comorbidity Correlates of Death Among New Veterans of Iraq and Afghanistan Deployment.

Authors:  Laurel A Copeland; Erin P Finley; Mary J Bollinger; Megan E Amuan; Mary Jo V Pugh
Journal:  Med Care       Date:  2016-12       Impact factor: 2.983

4.  Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.

Authors:  Stephen F Butler; Simon H Budman; Gilbert J Fanciullo; Robert N Jamison
Journal:  Clin J Pain       Date:  2010 Nov-Dec       Impact factor: 3.442

5.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R).

Authors:  Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison
Journal:  J Pain       Date:  2008-01-22       Impact factor: 5.820

6.  Validation of a brief Opioid Compliance Checklist for patients with chronic pain.

Authors:  Robert N Jamison; Marc O Martel; Robert R Edwards; Jing Qian; Kerry Anne Sheehan; Edgar L Ross
Journal:  J Pain       Date:  2014-08-01       Impact factor: 5.820

7.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

8.  Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients.

Authors:  Laura L Adams; Robert J Gatchel; Richard C Robinson; Peter Polatin; Noor Gajraj; Martin Deschner; Carl Noe
Journal:  J Pain Symptom Manage       Date:  2004-05       Impact factor: 3.612

9.  The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs.

Authors:  Stephanie Lake; Kanna Hayashi; Jane Buxton; M-J Milloy; Huiru Dong; Evan Wood; Julio Montaner; Thomas Kerr
Journal:  Drug Alcohol Depend       Date:  2015-09-30       Impact factor: 4.492

10.  Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors.

Authors:  Ingrid A Binswanger; Carolyn Nowels; Karen F Corsi; Jason Glanz; Jeremy Long; Robert E Booth; John F Steiner
Journal:  Addict Sci Clin Pract       Date:  2012-03-15
View more
  9 in total

1.  Between- and within-person associations between opioid overdose risk and depression, suicidal ideation, pain severity, and pain interference.

Authors:  Charles M Cleland; Alex S Bennett; Luther Elliott; Andrew Rosenblum; Peter C Britton; Brett Wolfson-Stofko
Journal:  Drug Alcohol Depend       Date:  2019-11-14       Impact factor: 4.492

2.  Opioid-Involved Overdose Among Male Afghanistan/Iraq-Era U.S. Military Veterans: A Multidimensional Perspective.

Authors:  Alex S Bennett; Luther Elliott; Andrew Golub; Brett Wolfson-Stofko; Honoria Guarino
Journal:  Subst Use Misuse       Date:  2017-06-16       Impact factor: 2.164

3.  Recent Overdose Experiences in a Community Sample of Military Veterans Who Use Opioids.

Authors:  Enrique R Pouget; Alex S Bennett; Luther Elliott; Andrew Rosenblum; Peter C Britton
Journal:  J Drug Issues       Date:  2017-03-22

4.  Military veterans' overdose risk behavior: Demographic and biopsychosocial influences.

Authors:  Alex S Bennett; J Alexander Watford; Luther Elliott; Brett Wolfson-Stofko; Honoria Guarino
Journal:  Addict Behav       Date:  2019-06-25       Impact factor: 3.913

5.  Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder.

Authors:  Hilary S Connery; Nadine Taghian; Jungjin Kim; Margaret Griffin; Ian R H Rockett; Roger D Weiss; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-10-05       Impact factor: 4.492

6.  Validation of the Opioid Overdose Risk Behavior Scale, version 2 (ORBS-2).

Authors:  Luther Elliott; Dev Crasta; Maria Khan; Alexis Roth; Traci Green; Andrew Kolodny; Alex S Bennett
Journal:  Drug Alcohol Depend       Date:  2021-04-20       Impact factor: 4.852

Review 7.  Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.

Authors:  Alex S Bennett; Luther Elliott
Journal:  Transl Res       Date:  2021-03-05       Impact factor: 10.171

8.  Psychiatric symptoms and recent overdose among people who use heroin or other opioids: Results from a secondary analysis of an intervention study.

Authors:  Michael Fendrich; Jessica Becker; Jennifer Hernandez-Meier
Journal:  Addict Behav Rep       Date:  2019-08-06

9.  Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain.

Authors:  Phillip O Coffin; Christopher Rowe; Natalie Oman; Katie Sinchek; Glenn-Milo Santos; Mark Faul; Rita Bagnulo; Deeqa Mohamed; Eric Vittinghoff
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.